ArtProtein is built around CHO and HEK expression platforms for antibodies and recombinant proteins, with development approaches designed for efficient scale-up and tech transfer into GMP manufacturing.
Primary platform for monoclonal antibodies and many Fc-fusion proteins. We support both stable and transient CHO expression to balance speed and long-term supply requirements, with development concepts that transfer cleanly into process-controlled bioreactors and partner CDMOs.
Suitable for certain complex or multi-subunit proteins and specific post-translational profiles. Transient HEK expression is used for rapid generation of early material, while stable HEK options are considered when this platform is preferred for later development.
Stable and transient expression workflows are configured to provide material for feasibility assessments, assay setup, tox-enabling studies, and early process characterization in a way that supports later CMC and regulatory use.
Development starts in scale-down systems such as deep-well plates, shake flasks, and small bioreactors to efficiently explore design spaces and identify promising operating ranges early.
Learnings from scale-down models are translated into process-controlled bioreactors at bench and larger scales, with attention to parameters that will matter during tech transfer and GMP manufacturing.
Design of experiments (DoE) is used where appropriate to evaluate feeds, process parameters, and control strategies, helping to define robust operating spaces rather than single-point conditions.
Development planning includes consideration of which assays are needed at each stage to support decisions on clone selection, process conditions, and purification strategies.
Data from small-scale, transient, and stable expression studies is organized in a way that can be reused in CMC documentation and USDA 9CFR–related submissions, not just in internal reports.
Particular care is taken to show how observations from small-scale experiments relate to performance in process-controlled bioreactors, supporting clearer regulatory and tech-transfer narratives.